Daiichi Sankyo/Ranbaxy leverage Mexican unit to launch innovative drugs

Japan's Daiichi Sankyo and majority-owned Indian drugmaker and Ranbaxy Laboratories announced specific plans to introduce innovator products of the Japanese firm in Mexico through the marketing division that was created last year within Ranbaxy's Mexican subsidiary, Ranbaxy Mexico SA de CV last year (The Pharma Letter October 12, 2009).

Initially, Daiichi Sankyo and Ranbaxy Mexico have agreed to commercialize olmesartan medoxomil, an antihypertensive discovered by Daiichi Sankyo, in Mexico.

Additionally, the companies have agreed to promote prasugrel, an antiplatelet co-developed by Daiichi Sankyo and US drug major Eli Lilly. Prasugrel will be co-promoted by Lilly's affiliate in Mexico.